Neola Medical AB (SE:NEOLA)
:NEOLA
Want to see SE:NEOLA full AI Analyst Report?
NEOLA Stock Chart & Stats
kr1.08
kr0.08(3.31%)
At close: 4:00 PM EST
kr1.08
kr0.08(3.31%)
Day’s Range― - ―
52-Week Rangekr0.58 - kr2.94
Previous CloseN/A
Volume18.12K
Average Volume (3M)12.79K
Market Cap
kr104.77M
Enterprise Valuekr68.00M
Total Cash (Recent Filing)kr16.12M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.33
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding124,720,375
10 Day Avg. Volume10,323
30 Day Avg. Volume12,794
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.07
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr9.10M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthZero reported debt and meaningful equity reduce solvency risk and give the company financial flexibility. For a pre-revenue medical device firm, low leverage extends runway for R&D and regulatory work, lowering immediate pressure for dilutive financing and enabling strategic milestone pacing.
Lean Cost StructureA very small headcount implies a lean operating model and lower fixed costs. This improves capital efficiency during product development, stretches available cash, and allows management to focus limited resources on critical clinical, regulatory, and commercialization milestones without large overhead commitments.
Stable Cash Burn TrajectoryOperating cash outflows are negative but have remained roughly stable rather than accelerating. Predictable, non-escalating burn gives management time to pursue commercialization/regulatory steps and reduces the immediacy of refinancing, improving the durability of the company’s near-term plan if milestones progress as planned.
Bears Say
No RevenueEffectively zero revenue over multiple years shows the company has not commercialized its core monitoring system. Absence of sales prevents validation of product-market fit, forces continued R&D spending without offsetting cash inflows, and increases dependence on external financing to sustain operations.
Negative Operating Cash FlowPersistent negative operating and free cash flow undermines the company’s ability to self-fund growth or commercialization. Continued cash burn necessitates external capital, which risks dilution, fundraising execution risk, or constrained investment in trials and commercialization that are critical to achieving sustainable revenue.
Sustained Operating LossesMaterial net losses and deeply negative EBITDA/EBIT across years indicate prolonged pre-commercial phase. Continued losses erode equity over time, limit flexibility for strategic initiatives, and raise execution risk that product adoption or regulatory milestones may not arrive in time to avoid funding shortfalls.
Neola Medical AB News
NEOLA FAQ
What was Neola Medical AB’s price range in the past 12 months?
Neola Medical AB lowest stock price was kr0.58 and its highest was kr2.94 in the past 12 months.
What is Neola Medical AB’s market cap?
Neola Medical AB’s market cap is kr104.77M.
When is Neola Medical AB’s upcoming earnings report date?
Neola Medical AB’s upcoming earnings report date is Aug 20, 2026 which is in 67 days.
How were Neola Medical AB’s earnings last quarter?
Neola Medical AB released its earnings results on May 19, 2026. The company reported -kr0.044 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.044.
Is Neola Medical AB overvalued?
According to Wall Street analysts Neola Medical AB’s price is currently Overvalued.
Does Neola Medical AB pay dividends?
Neola Medical AB does not currently pay dividends.
What is Neola Medical AB’s EPS estimate?
Neola Medical AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neola Medical AB have?
Neola Medical AB has 124,720,375 shares outstanding.
What happened to Neola Medical AB’s price movement after its last earnings report?
Neola Medical AB reported an EPS of -kr0.044 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.863%.
Which hedge fund is a major shareholder of Neola Medical AB?
Currently, no hedge funds are holding shares in SE:NEOLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Neola Medical AB
Neola Medical AB (publ) specializes in developing advanced medical devices for the continuous pulmonary assessment of premature babies. At the core of its offerings is NEOLA, a sophisticated medical instrument critical for neonatal intensive care. This device facilitates ongoing lung function monitoring and generates immediate alerts for critical, life-threatening complications. It achieves this by accurately tracking changes in lung volume and oxygen gas concentration. The ultimate goal of NEOLA is to enhance intensive care and promote healthier outcomes for infants born preterm. The company, formerly known as GPX Medical AB, officially changed its name to Neola Medical AB (publ) in June 2022. Neola Medical AB (publ) was established in 2016 and is headquartered in Lund, Sweden.
Technical Analysis
―
Clinical Laserthermia Systems AB Class B
―
Luxbright AB
―
Nosa Plugs AB
―
Arcoma AB
―